Absci (ABSI) investor relations material

Platform overview and strategic focus

• AI-driven platform targets challenging drug targets like GPCRs and ion channels, aiming for differentiated assets.

• Origin-1 model enables design against zero prior epitopes, with early pipeline assets targeting difficult indications.

• Internal pipeline includes ABS-201, focused on androgenetic alopecia (AGA) and endometriosis.

• Selective advancement of programs based on ROI and market potential, with AGA prioritized.

Androgenetic alopecia (AGA) program

• AGA affects 80 million in the US; current therapies lack efficacy, convenience, and adherence.

• ABS-201 offers a novel subcutaneous injection, potentially providing durable hair growth with minimal dosing.

• Mechanism targets peripheral prolactin, shown to drive hair miniaturization; blocking it promotes hair growth and pigmentation.

• Key endpoints include target area hair count and restoration of pigmentation, with interim and final readouts at 13 and 26 weeks.

• Topline safety and PK data expected in 1H 2024; interim efficacy in 2H 2024; full readout in 2027.

Endometriosis program

• Prolactin inhibition supported by animal and competitor data; dual mechanism addresses lesion formation and pain.

• Phase II trial planned for Q4 2024, focusing on pain reduction as primary endpoint.

• Patient selection will emphasize baseline pain and appropriate diagnostic criteria.

• Interim efficacy readout for endometriosis expected in 2H 2027.